Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics insider Christopher Horan reported two dispositions of common stock tied to restricted stock unit vesting and tax withholding. On 05/15/2025 he had 1,341 shares withheld at an effective price of $2.13, reducing his direct ownership to 83,659 shares. On 08/15/2025 he had 3,577 shares withheld at $2.75, reducing his direct ownership to 80,082 shares. The filing identifies Horan as Chief Tech Operations Officer and was signed by an attorney-in-fact on 08/18/2025. The form states these share reductions "represent shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards," indicating these were not open-market sales but withholding transactions connected to equity compensation.
Artiva Biotherapeutics reported a Form 144 notice showing a planned sale of 25,500 common shares held as Restricted Stock Units that were acquired and are to be sold on 08/15/2025. The broker listed is Morgan Stanley Smith Barney LLC and the planned transaction lists an aggregate market value of $68,850 based on 25,500 shares. The filing records 24,425,762 shares outstanding and identifies NASDAQ as the exchange. The filer reports no securities sold in the prior three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.
The notice appears routine: shares arose from company RSUs, the sale is executed through a major broker, and there are no prior sales reported in the three-month lookback period.
RA Capital Management reported changes in beneficial ownership of Artiva Biotherapeutics (ARTV) through a Form 4 filing. The key transaction involves the grant of 13,750 stock options to Laura Stoppel, a Partner at RA Capital who serves on Artiva's board, on June 24, 2025.
Key details of the stock option grant:
- Exercise price: $1.61 per share
- Vesting date: Earlier of June 24, 2026, or 2026 annual stockholder meeting
- Expiration date: June 23, 2035
Notable governance structure: The options are held for the benefit of RA Capital's funds (Healthcare Fund, Nexus Fund, and Nexus Fund III) and a managed account. Dr. Stoppel must transfer any proceeds to RA Capital to offset advisory fees. The filing includes multiple reporting persons, including Peter Kolchinsky and Rajeev Shah as managing members of RA Capital Management GP, who maintain significant ownership positions as both directors and 10% owners.
Artiva Biotherapeutics, Inc. (ARTV) disclosed a routine insider transaction in a Form 4 filing. On 24 June 2025, director Alison Moore received a stock option for 13,750 common shares at an exercise price of $1.61 per share. The option vests in full on the earlier of 24 June 2026 or the company’s 2026 annual shareholder meeting and expires on 23 June 2035. Following the grant, Moore beneficially owns 13,750 derivative securities, held directly. No shares were bought or sold in the open market, and there were no accompanying cash transactions.
The filing reflects standard director compensation and does not signal changes to Artiva’s operating outlook, capital structure, or near-term liquidity.
Form 4 Filing Details: Daniel G. Baker, Director of Artiva Biotherapeutics (ARTV), received a stock option grant for 13,750 shares of common stock on June 24, 2025.
Key transaction details:
- Option exercise price set at $1.61 per share
- Full vesting occurs on the earlier of June 24, 2026, or the 2026 annual stockholder meeting
- Options expire on June 23, 2035
- Transaction reported as a direct ownership
This equity compensation grant appears to be part of the company's director compensation program. The filing was signed by Neha Krishnamohan as attorney-in-fact on June 26, 2025.
Elizabeth L. Hougen, Director at Artiva Biotherapeutics, reported receiving a stock option grant on June 24, 2025. The derivative securities transaction involved:
- Grant of 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options will vest fully on the earlier of June 24, 2026, or the date of the 2026 annual stockholder meeting
- Options expire on June 23, 2035
This Form 4 filing represents a standard director compensation equity grant. The options were granted with a 1-year cliff vesting schedule, suggesting alignment with the company's annual director service period. The transaction was executed under direct ownership, with the filing made through an attorney-in-fact on June 26, 2025.